Top-News

Carlisle Aktie News

Aktie
WKN:  871884 ISIN:  US1423391002 US-Symbol:  CSL Branche:  Baumaterialien Land:  USA
280,20 €
+3,80 €
+1,37%
13:14:19 Uhr
Depot/Watchlist
Marktkapitalisierung *
11,96 Mrd. €
Streubesitz
-
KGV
13,24
Dividende
1,10 $
Dividendenrendite
0,34%
neu: Nachhaltigkeits-Score
15 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 7,29: MG2J1E
Werbung

Carlisle News

28.10.25 - PR Newswire
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der „2025 Facility of the Year Awards" ausgezeichnet
CSL wurde von der International Society for Pharmaceutical Engineering (ISPE) als Gesamtsieger der „2025 Facility of the Year Awards" ausgezeichnet PR Newswire
26.10.25 - PR Newswire
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire
26.10.25 - PR Newswire
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) PR Newswire
21.10.25 - PR Newswire
Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
Recent RWE Data Show Cell-​Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-​Confirmed Influenza in Pediatric and Adult Populations Relative to ...
26.09.25 - PR Newswire
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy PR Newswire
04.07.25 - wallstreetONLINE Redaktion
Aktien mit Potenzial: JPMorgan’s "Analyst Focus List" für Juli
JPMorgan hat für Juli seine "Analyst Focus List" aktualisiert: Darunter spannende Aktien wie Scholar Rock, Carlisle und Boeing mit viel Potenzial. Das sind die Top-​Empfehlungen ...
16.06.25 - PR Newswire
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start
U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-​gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-...
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
23.05.25 - PR Newswire
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
29.04.25 - PR Newswire
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy PR Newswire
20.02.25 - PR Newswire
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-​Activated Factor XII Monoclonal Antibody for the ...
14.02.25 - PR Newswire
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-​amplifying mRNA COVID-19 Vaccine PR Newswire
13.02.25 - PR Newswire
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) PR Newswire
07.02.25 - PR Newswire
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-​drlb) Four Years Post-​Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with ...
06.02.25 - PR Newswire
Tavneos® (Avacopan) in der Schweiz jetzt erstattet für die Behandlung der ANCA-assoziierten Vaskulitis
Tavneos® (Avacopan) in der Schweiz jetzt erstattet für die Behandlung der ANCA-​assoziierten Vaskulitis PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,63%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »